Nutritionally enhanced fraction from rice bran and method of lowering insulin resistance using same
View Patent ↗Nutritionally enhanced nutraceutical Hydrophilic and Lipophilic Rice Bran Fractions from rice bran are provided, as well as a method of using the same to reduce Insulin Resistance in animals, especially humans with pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome. Provided in various example embodiments are mixtures of elevated levels of nutraceutical compounds, including but not limited to gamma-oryzanol, inositol, ferulic acid, tocotrienols and phytosterols and pharmaceutical and nutritional compositions thereof. Steps are provided including evaluating insulin resistance parameters, initiating therapy including providing therapeutic amounts of Hydrophilic and Lipophilic Rice Bran Fractions from rice bran to treat pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome, managing compliance with the therapy, and monitoring and reevaluating the therapy.
1. A nutraceutical, comprising: a therapeutic amount of a hydrophilic and lipophilic rice bran fraction prepared by an enzyme treatment, wherein said amount is sufficient to treat Insulin Resistance in a user, and wherein said fraction has a total Oxygen Radical Absorbance Capacity of at least 20,500 micromoles Trolox equivalents per 100 grams of said fraction, and wherein said enzyme treatment comprises the use of a beta-glucanase enzyme, a thermotolerant protease enzyme mix derived from Carica papaya , and a thermostable alpha-amylase enzyme.
2. The nutraceutical of claim 1 , further comprising: therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat pre-diabetes in a user.
3. The nutraceutical of claim 1 , further comprising: therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat Type 2 diabetes in a user.
4. The nutraceutical of claim 1 , further comprising: therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat Metabolic Syndrome in a user.
5. The nutraceutical of claim 1 , wherein: the therapeutic amounts of hydrophilic and lipophilic fractions from rice bran comprise 5 grams to 30 grams of the hydrophilic and lipophilic fractions from rice bran.
6. The nutraceutical of claim 1 , wherein: the therapeutic amounts of hydrophilic and lipophilic fractions from rice bran comprise 10 grams to 20 grams of the hydrophilic and lipophilic fractions from rice bran.
7. The nutraceutical of claim 1 , wherein the hydrophilic and lipophilic fractions from rice bran are in a solution, suspension, or syrup, and are ready for oral administration.
8. The nutraceutical of claim 1 , wherein the hydrophilic and lipophilic fractions from rice bran are in a dry powder composition adapted to be combined with water prior to administration.
9. The nutraceutical of claim 1 , wherein the hydrophilic and lipophilic fractions from rice bran are in a liquid concentrate adapted to be diluted prior to administration.
10. The nutraceutical of claim 1 , wherein the hydrophilic and lipophilic fractions from rice bran are in a tablet ready for oral administration.
11. The nutraceutical of claim 1 , wherein the hydrophilic and lipophilic fractions from rice bran are in a capsule ready for oral administration.
12. The nutraceutical of claim 1 , further comprising two or more of any of the following: Alpha lipoic acid; Coenzyme Q; Vitamin C; Vitamin E; Selenium; Chromium; Zinc; Chromium; Boron; Carnitine; Vitamin B3; Vitamin B12; Biotin; Folate; Vitamin B6; Vitamin B5; Vitamin 0; Vitamin K; Calcium; Potassium; Magnesium; Ginseng; Bilberry; Ginkgo biloba ; Garlic; Onions.
13. A method of treating Insulin Resistance in a user, comprising the steps of: providing the user with a nutraceutical comprising a therapeutic amount of a hydrophilic and lipophilic rice bran fraction prepared by an enzyme treatment, wherein said amount is sufficient to treat Insulin Resistance in the user, and wherein said fraction has a total Oxygen Radical Absorbance Capacity of at least 20,500 micromoles Trolox equivalents per 100 grams of said fraction, and wherein said enzyme treatment comprises the use of a beta-glucanase enzyme, a thermotolerant protease enzyme mix derived from Carica papaya , and a thermostable alpha-amylase enzyme.
14. The method of claim 13 , further comprising the step of: providing the user with a nutraceutical comprising therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat pre-diabetes in a user.
15. The method of claim 13 , further comprising the step of: providing the user with a nutraceutical comprising therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat Type 2 diabetes in a user.
16. The method of claim 13 , further comprising the step of: providing the user with a nutraceutical comprising therapeutic amounts of hydrophilic and lipophilic fractions from rice bran sufficient to treat Metabolic Syndrome in a user.
17. The method of claim 13 , wherein: the therapeutic amounts of hydrophilic and lipophilic fractions from rice bran comprise 5 grams to 30 grams of the hydrophilic and lipophilic fractions from rice bran.
18. The method of claim 13 , wherein: the therapeutic amounts of hydrophilic and lipophilic fractions from rice bran comprise 10 grams to 20 grams of the hydrophilic and lipophilic fractions from rice bran.
19. The method of claim 13 , wherein: the nutraceutical further comprises two or more of any of the following: Alpha lipoic acid; Coenzyme Q; Vitamin C; Vitamin E; Selenium; Chromium; Zinc; Chromium; Boron; Carnitine; Vitamin B3; Vitamin B12; Biotin; Folate; Vitamin B6; Vitamin B5; Vitamin D; Vitamin K; Calcium; Potassium; Magnesium; Ginseng; Bilberry; Ginkgo biloba ; Garlic; Onions.
20. A method of treating Insulin Resistance in a user, comprising the steps of: the user consuming a nutraceutical comprising a therapeutic amount of a hydrophilic and lipophilic rice bran fraction prepared by an enzyme treatment, wherein said amount is sufficient to treat Insulin Resistance in the user, and wherein said fraction has a total Oxygen Radical Absorbance Capacity of at least 20,500 micromoles Trolox equivalents per 100 grams of said fraction, and wherein said enzyme treatment comprises the use of a beta-glucanase enzyme, a thermotolerant protease enzyme mix derived from Carica papaya , and a thermostable alpha-amylase enzyme.